- Fourth-quarter revenue, unaudited, is expected to be at least $1.03 billion, which represents an increase of 26% over the same period of 2022
- US revenue is expected to be around $765 million in the December quarter, which is up 26% over the fourth quarter of the prior year
- At $265 million, international revenue is estimated to be higher by 27% from the prior-year quarter
- Stelo, the company’s new glucose sensor for people with type-2 diabetes who do not use insulin, has been submitted to the FDA for review
- For FY24, the company expects revenues of $4.15-4.35 billion, representing expected organic growth of 16-21% Year-over-year
- Full-year adjusted gross profit margin is expected to be approximately 63 – 64%
- The management is looking for an adjusted operating margin of around 20% for fiscal 2024
Market News
Earnings Summary: Highlights of DexCom’s Q4 2023 financial results
Healthcare company DexCom, Inc. (NASDAQ: DXCM) announced preliminary results for the fourth quarter of 2023, reporting an estimated double-digit increase in revenues. Fourth-quarter revenue, unaudited, is expected to be at least $1.03 billion, which represents an increase of 26% over the same period of 2022 US revenue is expected to be around $765 million in […]
“Healthcare company DexCom, Inc. (NASDAQ: DXCM) announced preliminary results for the fourth quarter of 2023, reporting an estimated double-digit increase in revenues. Fourth-quarter revenue, unaudited, is expected to be at least $1.03 billion, which represents an increase of 26% over the same period of 2022 US revenue is expected to be around $765 million in […]
· January 9, 2024
Healthcare company DexCom, Inc. (NASDAQ: DXCM) announced preliminary results for the fourth quarter of 2023, reporting an estimated double-digit increase in revenues.
ADVERTISEMENT